Is ORKA or INBX more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -21.65% -20.88% Inhibrx Biosciences N/A -563.90% -83.48%

Does the media prefer ORKA or INBX?

In the previous week, Oruka Therapeutics had 14 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 23 mentions for Oruka Therapeutics and 9 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.92 beat Oruka Therapeutics' score of 0.55 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 6 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor MIRM or INBX?

In the previous week, Inhibrx Biosciences had 4 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 9 mentions for Inhibrx Biosciences and 5 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat Inhibrx Biosciences' score of 0.92 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer INBX or TVTX?

In the previous week, Travere Therapeutics had 9 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 18 mentions for Travere Therapeutics and 9 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.92 beat Travere Therapeutics' score of 0.69 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Travere Therapeutics 2 Very Positive mention(s) 10 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SRRK or INBX more profitable?

Scholar Rock's return on equity of -160.19% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Inhibrx Biosciences N/A -563.90% -83.48%

Does the media refer more to SRRK or INBX?

In the previous week, Scholar Rock and Scholar Rock both had 9 articles in the media. Inhibrx Biosciences' average media sentiment score of 0.92 beat Scholar Rock's score of 0.79 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Inhibrx Biosciences (INBX) Competitors

$99.61 -0.79 (-0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$99.66 +0.05 (+0.05%)

As of 07:49 PM Eastern

Compare

INBX vs. ORKA, KNSA, MIRM, TVTX, and SRRK

Should you buy Inhibrx Biosciences stock or one of its competitors? Inhibrx Biosciences's main competitors and comparable companies include Oruka Therapeutics (ORKA), Kiniksa Pharmaceuticals International (KNSA), Mirum Pharmaceuticals (MIRM), Travere Therapeutics (TVTX), and Scholar Rock (SRRK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Inhibrx Biosciences compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

In the previous week, Oruka Therapeutics had 14 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 23 mentions for Oruka Therapeutics and 9 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.92 beat Oruka Therapeutics' score of 0.55 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	6 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Oruka Therapeutics has higher earnings, but lower revenue than Inhibrx Biosciences. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Inhibrx Biosciences	$1.30M	1,127.89	-$140.05M	-$8.88	N/A

Oruka Therapeutics has a beta of -0.34, meaning that its stock price is 134% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.66, meaning that its stock price is 266% more volatile than the broader market.

Oruka Therapeutics' return on equity of -21.65% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Oruka Therapeutics currently has a consensus price target of $128.91, suggesting a potential upside of 52.63%. Inhibrx Biosciences has a consensus price target of $197.50, suggesting a potential upside of 98.27%. Given Inhibrx Biosciences' higher probable upside, analysts clearly believe Inhibrx Biosciences is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Oruka Therapeutics beats Inhibrx Biosciences on 8 of the 14 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Kiniksa Pharmaceuticals International currently has a consensus target price of $87.38, indicating a potential upside of 16.38%. Inhibrx Biosciences has a consensus target price of $197.50, indicating a potential upside of 98.27%. Given Inhibrx Biosciences' higher probable upside, analysts clearly believe Inhibrx Biosciences is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Inhibrx Biosciences had 5 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 9 mentions for Inhibrx Biosciences and 4 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.21 beat Inhibrx Biosciences' score of 0.92 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.66, suggesting that its share price is 266% more volatile than the broader market.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Inhibrx Biosciences' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	8.65	$59.01M	$0.97	77.40
Inhibrx Biosciences	$1.30M	1,127.89	-$140.05M	-$8.88	N/A

Summary

Kiniksa Pharmaceuticals International beats Inhibrx Biosciences on 11 of the 17 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Mirum Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.66, meaning that its stock price is 266% more volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.17	-$23.36M	-$14.55	N/A
Inhibrx Biosciences	$1.30M	1,127.89	-$140.05M	-$8.88	N/A

In the previous week, Inhibrx Biosciences had 4 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 9 mentions for Inhibrx Biosciences and 5 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat Inhibrx Biosciences' score of 0.92 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

82.5% of Inhibrx Biosciences shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Inhibrx Biosciences has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Mirum Pharmaceuticals presently has a consensus price target of $137.31, indicating a potential upside of 53.08%. Inhibrx Biosciences has a consensus price target of $197.50, indicating a potential upside of 98.27%. Given Inhibrx Biosciences' higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Mirum Pharmaceuticals and Inhibrx Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Travere Therapeutics?

Inhibrx Biosciences (NASDAQ:INBX) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

Inhibrx Biosciences has a beta of 3.66, suggesting that its share price is 266% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

82.5% of Inhibrx Biosciences shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Inhibrx Biosciences has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Travere Therapeutics' return on equity of -55.15% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Travere Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Travere Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,127.89	-$140.05M	-$8.88	N/A
Travere Therapeutics	$490.73M	11.42	-$25.55M	-$0.46	N/A

In the previous week, Travere Therapeutics had 9 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 18 mentions for Travere Therapeutics and 9 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.92 beat Travere Therapeutics' score of 0.69 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Travere Therapeutics	2 Very Positive mention(s)	10 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences presently has a consensus target price of $197.50, suggesting a potential upside of 98.27%. Travere Therapeutics has a consensus target price of $69.50, suggesting a potential upside of 16.92%. Given Inhibrx Biosciences' higher probable upside, research analysts clearly believe Inhibrx Biosciences is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Inhibrx Biosciences beats Travere Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

In the previous week, Scholar Rock and Scholar Rock both had 9 articles in the media. Inhibrx Biosciences' average media sentiment score of 0.92 beat Scholar Rock's score of 0.79 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Inhibrx Biosciences has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Inhibrx Biosciences	$1.30M	1,127.89	-$140.05M	-$8.88	N/A

Scholar Rock presently has a consensus target price of $66.75, suggesting a potential upside of 37.26%. Inhibrx Biosciences has a consensus target price of $197.50, suggesting a potential upside of 98.27%. Given Inhibrx Biosciences' higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	2.94
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Scholar Rock has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.66, indicating that its stock price is 266% more volatile than the broader market.

Scholar Rock's return on equity of -160.19% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 10.3% of Scholar Rock shares are held by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Inhibrx Biosciences beats Scholar Rock on 8 of the 14 factors compared between the two stocks.

Get Inhibrx Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INBX vs. The Competition

Export

Metric	Inhibrx Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.48B	$3.93B	$7.29B	$13.10B
Dividend Yield	N/A	3.63%	2.52%	13.51%
P/E Ratio	-11.22	8.30	213.99	21.16
Price / Sales	1,127.89	1,331.56	618.37	86.16
Price / Cash	N/A	118.05	79.23	52.93
Price / Book	181.11	15.28	10.43	6.30
Net Income	-$140.05M	-$22.86M	$3.49B	$359.77M
7 Day Performance	-8.91%	-2.94%	-1.25%	-0.17%
1 Month Performance	-18.83%	-8.97%	-4.51%	-4.06%
1 Year Performance	212.85%	31.46%	16.42%	6.09%

Inhibrx Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INBX Inhibrx Biosciences	3.8838 of 5 stars	$99.61 -0.8%	$197.50 +98.3%	+238.0%	$1.48B	$1.30M	N/A	110	Insider Trade
ORKA Oruka Therapeutics	2.9532 of 5 stars	$94.55 +1.3%	$133.00 +40.7%	+459.9%	$6.18B	N/A	N/A	68	Trending News Analyst Forecast
KNSA Kiniksa Pharmaceuticals International	3.8862 of 5 stars	$78.00 -0.2%	$87.38 +12.0%	+108.8%	$6.10B	$677.56M	80.41	366	News Coverage Positive News
MIRM Mirum Pharmaceuticals	2.885 of 5 stars	$91.39 -0.7%	$137.31 +50.2%	+20.3%	$5.97B	$521.31M	N/A	433
TVTX Travere Therapeutics	1.8932 of 5 stars	$60.28 -4.1%	$68.10 +13.0%	+148.3%	$5.93B	$490.73M	N/A	497	Analyst Forecast Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INBX) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibrx Biosciences (INBX) Competitors

INBX vs. ORKA, KNSA, MIRM, TVTX, and SRRK

How does Inhibrx Biosciences compare to Oruka Therapeutics?

Summary

How does Inhibrx Biosciences compare to Kiniksa Pharmaceuticals International?

Summary

How does Inhibrx Biosciences compare to Mirum Pharmaceuticals?

Summary

How does Inhibrx Biosciences compare to Travere Therapeutics?

Summary

How does Inhibrx Biosciences compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibrx Biosciences (INBX) Competitors

INBX vs. ORKA, KNSA, MIRM, TVTX, and SRRK

How does Inhibrx Biosciences compare to Oruka Therapeutics?

Does the media prefer ORKA or INBX?

Which has better earnings & valuation, ORKA or INBX?

Which has more volatility and risk, ORKA or INBX?

Is ORKA or INBX more profitable?

Do analysts recommend ORKA or INBX?

Do insiders & institutionals hold more shares of ORKA or INBX?

Summary

How does Inhibrx Biosciences compare to Kiniksa Pharmaceuticals International?

Do analysts rate KNSA or INBX?

Does the media refer more to KNSA or INBX?

Which has more risk & volatility, KNSA or INBX?

Is KNSA or INBX more profitable?

Do institutionals & insiders have more ownership in KNSA or INBX?

Which has better earnings & valuation, KNSA or INBX?

Summary

How does Inhibrx Biosciences compare to Mirum Pharmaceuticals?

Which has more risk & volatility, MIRM or INBX?

Which has better earnings and valuation, MIRM or INBX?

Does the media favor MIRM or INBX?

Do institutionals and insiders believe in MIRM or INBX?

Is MIRM or INBX more profitable?

Do analysts recommend MIRM or INBX?

Summary

How does Inhibrx Biosciences compare to Travere Therapeutics?

Which has more volatility & risk, INBX or TVTX?

Do insiders and institutionals have more ownership in INBX or TVTX?

Is INBX or TVTX more profitable?

Which has stronger earnings & valuation, INBX or TVTX?

Does the media prefer INBX or TVTX?

Do analysts prefer INBX or TVTX?

Summary

How does Inhibrx Biosciences compare to Scholar Rock?

Does the media refer more to SRRK or INBX?

Which has preferable earnings and valuation, SRRK or INBX?

Do analysts prefer SRRK or INBX?

Which has more risk and volatility, SRRK or INBX?

Is SRRK or INBX more profitable?

Do institutionals & insiders hold more shares of SRRK or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools